ANZGOG ASM 2025

Handbook Hyatt Hotel, Canberra, Australia

#ANZGOG2025ASM

anzgogasm.org.au

Thank you to our Partners

PRESENTING PARTNER

MAJOR PARTNER

SYMPOSIUM PARTNERS

DINNER PARTNER

WELCOME RECEPTION PARTNER

COFFEE CART PARTNER

POSTER SESSION PARTNER NURSES WORKSHOP PARTNER

EXHIBITORS

2

Information for Delegates

Registration Desk The Registration Desk is located in The Atrium. Any enquiries can be directed to the ASN staff onsite. Social Media Hyatt Hotel, 120 Commonwealth Avenue Canberra, Australian Capital Territory, Australia, 2600 Telephone: (02) 6270 1234 Venue Directory

Shuttles For those staying at offsite hotels, there will be shuttles running to and from the conference venue. Please be outside your hotel at the pick-up time outlined below. Wednesday 5 March 2025 Pick up location: Hyatt Hotel Canberra Pick up time: 8:45pm Drop off locations: • Burbury Hotel, Little National Hotel, Hotel Kurrajong Thursday 6 March 2025 Pick up locations: • Burbury Hotel, Little National Hotel, Hotel Kurrajong Pick up times: • Shutte 1 - 06:45am (for Breakfast Symposium attendees) • Shuttle 2 - 07:45am (for all other attendees) Drop off location: Hyatt Hotel Canberra Pick up location: Hyatt Hotel Canberra Pick up time: 5:15pm Drop off locations: • Burbury Hotel, Little National Hotel, Hotel Kurrajong Conference Dinner Pick up location – Hyatt Hotel, Burbury Hotel, Little National Drop off location – National Gallery of Australia Pick up location – National Gallery of Australia Pick up time – 11:15pm Drop off location – Hyatt Hotel, Burbury Hotel, Little National Hotel, Hotel Kurrajong Friday 7 March 2025 Pick up locations: • Burbury Hotel, Little National Hotel, Hotel Kurrajong Pick up time: • Shutte 1 - 06:45am (for Breakfast Symposium attendees) • Shuttle 2 - 07:45am (for all other attendees) Hotel, Hotel Kurrajong Pick up time – 6:40pm

We invite all attendees to use the official conference hashtag #ANZGOG2025ASM when posting about the conference on social media. Adding #ANZGOG2025ASM to your post can help connect you with other conference attendees. Search for #ANZGOG2025ASM on X (formerly known as Twitter) throughout the program to share and engage with highlights from colleagues. Conference App Download the official Conference App to access the latest information. You can flag sessions of interest, view floor plans, read abstracts and search for speakers by name. To download the Conference App onto your smart phone or tablet device follow these instructions:

1 Search for ‘Currinda’ via the App Store from the following platforms or simply scan the QR code

Apple Products App Store

Android Products Google Play

2 Once you have downloaded the App, you will be prompted to log in 3 First you must click on the ‘Client’ box and search for ‘ASN’ 4 Select ‘ASN’ from the list provided below and then you can log in with your email address and password you used to register for the conference You will be prompted to login each day. For further assistance please see ASN staff at the Registration Desk.

Drop off location: Hyatt Hotel Canberra Pick up location: Hyatt Hotel Canberra Pick up time: 4:30pm Drop off location: • Canberra Airport Limited seats available

The Smartphone ‘App’ will allow you to: • View the full conference program

• Save your favourite sessions and plan your day • View and search for speaker bios and abstracts • Take notes which will then be saved and downloaded from your registration profile. • View partners and exhibitors

3

PRE-CONFERENCE WORKSHOPS – WEDNESDAY 5 MARCH

ANZGOG Board Meeting – Assembly Room

8:00 AM

10:00 AM – 11:00 AM

ANZGOG’s Gynaecological Cancer Transformation Initiative Launch – Lavender Courtyard (invitation only)

MORNING TEA – The Atrium

10:30 AM

WORKSHOP: Trial design in the modern era of molecular medicine – Federation Ballroom South Chairs: Emma Allanson & Peey-Sei Kok

11:00 AM – 12:30 PM

Speakers

11:00 AM

New targets in Endometrial cancer, time to change our trial design

Peey-Sei Kok

11:10 AM

Pragmatic trials: value for money in low (and high) resource settings

Alison Brand AM

11:25 AM

Basket trials in gynae -current and future

Yoland Antill

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: the STRIVE study

11:45 AM

Paul Cohen

12:00 PM

Future trial design in cervical/vulva cancer

Jeff Goh

12:10 PM

Sample size calculation- phase 2 vs phase 3 trials

Chee Lee

12:20 PM

Panel Discussion

ALL

LUNCH – The Atrium

12:30 PM

1:30 PM – 3:30 PM

SPECIALTY WORKSHOPS

RADIATION ONCOLOGY Centenary 2

NURSES Federation Ballroom South Chairs: Bronwyn Jennings & Gwyneth Capes

STUDY COORDINATORS Centenary 1 Chair: Sue Brew

COMMUNITY VOLUNTEERS Centenary Centre *CLOSED WORKSHOP* Chair: Jane Power

Chairs: David Chang & Chelsie O’Connor

Sponsored by:

Pelvic Radiation: Indications, Treatment Planning Complexities and Case-Based Challenges – Carien Creutzberg

Promoting recovery following treatment for cancer – Sandie McCarthy (combined session with Community Volunteers) Nurse led models of care in gynaecological cancer – Anne Mellon

Navigating our legal obligations in clinical research – Nicola Amys

Promoting recovery following treatment for cancer – Sandie McCarthy (combined session with Nurses) EDEN update – Alison Evans & Kath Alsop ANZGOG’s Research process – John Andrews

1:30 PM

Documenting Success: Tips & Tricks for High-Quality Clinical Trial Data – Sally Mongta

2:30 PM

The Nurse Practitioner in Gynae Oncology – Shannon Philp

3:00 PM

AFTERNOON TEA – The Atrium / Canberra Room and Centenary Foyer

3:30 PM

4:00 PM – 5:30 PM

CONCURRENT SESSIONS

RADIATION ONCOLOGY Centenary 2

NURSES Federation Ballroom South Cancer research - Looking to the past to inform the future – Mei Krishnasamy

STUDY COORDINATORS Centenary 1 Informed Consent: Reflecting on the Past, Looking to the Future – Donna Long

COMMUNITY VOLUNTEERS Centenary Centre Pioneering Consumers in ANZGOG – Karen Livingstone AM, Wanda Lawson & Bree Stevens

GOROC Hybrid Meeting

4:00 PM

4:30 PM

Panel Discussion – Donna Long, Alison Davis & consumer TBC

Nursing education/IGCS update – Bronwyn Jennings & Gwyneth Capes

5:00 PM

POSTER SESSION The Gallery Room Chair: Michelle Harrison WELCOME RECEPTION The Atrium

Sponsored by:

5:30 PM

6:30 PM – 8:30 PM

Sponsored by:

PURE SCIENCE SYMPOSIUM – WEDNESDAY 5 MARCH – Chairs: Kylie Gorringe, Pamela Pollock, Nicola Meagher

Federation Ballroom North

Session 1 – Endometrial and ovarian cancer Chair: Pamela Pollock

11:00 AM – 12:30 PM

Speakers

Bradley Djirabidj Bell, Bryony Simcock and Pamela Pollock

11:00 AM

Welcome to Country, Acknowledgement, & Session introduction

11:05 AM

Using big data to find solutions to endometrial cancer prevention – how effective are weight loss treatments?

Susan Jordan

11:25 AM

Methylated circulating tumour DNA for detection of adenocarcinomas

Jean Winter

Defective chromatin remodelling present in less commonly diagnosed chemo-resistant ovarian cancer subtypes and in endometriosis, may reveal new therapeutic opportunities for these conditions Abstract 1: Targeting ARID1B in ARID1A-mutant Ovarian Clear Cell Carcinoma: A comprehensive drug repurposing approach combining in silico screening and in vitro validation

11:45 AM

Deborah Marsh

12:00 PM

Amani Alghalayini

12:15 PM

Abstract 2: Gene Expression Profiles to Predict Residual Disease After Cytoreductive Surgery for Ovarian Cancer

Brittney Harrington

LUNCH – The Atrium

12:30 PM

Session 2 – Ovarian cancer Chair: Kylie Gorringe

11:00 AM – 3:35 PM

Speakers

Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma Tumour-infiltrating B cells: the secret weapon promoting long-term survival in high-grade serous ovarian cancer?

1:30 PM

Tanjina Kader

1:50 PM

Dale Garsed

2:10 PM

Triggering an Anti-Tumour Immune Response in High-Grade Serous Ovarian Cancer

Jenny Zeng

2:30 PM

Towards a target for molecular imaging and treatment of epithelial ovarian cancers

John Hooper

Abstract 3: Deciphering chemotherapy resistance mechanisms in mucinous ovarian cancer via barcode clonal tracking Abstract 4: Novel preclinical models of ovarian carcinosarcoma enable the identification of potential effective combination therapies for future clinical benefit Abstract 5: Identification of potential therapeutic options to target the rare ovarian cancer subtype: Small-cell carcinoma of the ovary, hypercalcemic type

2:50 PM

Suad Abdirahman

3:05 PM

Holly Barker

3:20 PM

Natisha Field

AFTERNOON TEA – The Atrium and Canberra Room

3:35 PM

Session 3 - Cervical and rare gynaecological cancers Chair: Nicola Meagher

11:00 AM – 5:30 PM

Speakers

High throughput discovery of synergistic drug combinations for the treatment of Low Grade Serous Ovarian Carcinoma

4:00 PM

Kathleen Pishas

4:20 PM

Cervical cancer epidemiology – from data to policy

Megan Smith

4:40 PM

Immune markers of persistence and regression in cervical neoplasia

Merilyn Hibma

Abstract 6: Mapping the complexity of low-grade serous ovarian carcinoma through whole-genome and transcriptome sequencing

5:00 PM

Tania Moujaber

5:15 PM

Rapid Fire Abstract 1: Targeting the nucleoli as a strategy to treat ovarian cancer

Shalini Chelliah

Rapid Fire Abstract 2: Mutation profiling and molecular analysis in the INOVATe study: towards a personalised approach to the management of ovarian cancer patients

5:20 PM

Natalie Bouantoun

5:25 PM

Rapid Fire Abstract 3: Uncovering mechanisms of PARP inhibitor resistance in high-grade serous ovarian cancer

Zoe Phan

POSTER SESSION The Gallery Room Chair: Michelle Harrison WELCOME RECEPTION The Atrium

Sponsored by:

5:30 PM

6:30 PM – 8:30 PM

Sponsored by:

*Program subject to change.

5

CONFERENCE DAY 1 – THURSDAY 6 MARCH – Federation Ballroom

7:15 AM – 8:15 AM

Breakfast Symposium: Beyond Platinum: Future Horizons in Ovarian Cancer Management Moderator: Michael Friedlander AM

Sponsored by:

Bradley Djirabidj Bell, Bryony Simcock and Clare Scott

Welcome to Country, Acknowledgement, & Chair’s Welcome

8:30 AM

8:45 AM

ANZGOG: The inception of ANZGOG

Michael Friedlander AM

INTERNATIONAL KEYNOTES Session Chairs: Emma Allanson & Alison Davis

9:00 AM – 10:50 AM

Speakers

9:00 AM

Perspectives on Gynaecologic Oncology in a Limited Resource Setting

Lisa Bazzett-Matabele

9:30 AM

25 years of international collaboration

Carien Creutzberg

10:00 AM

Integrating ADCs in ovarian cancer management

David Tan

10:30 AM

Panel Discussion

All

MORNING TEA – The Atrium and Canberra Room

10:50 AM

CERVICAL and VULVA CANCERS Session Chairs: Lois Eva & Chelsie O’Connor

11:20 AM – 12:50 PM

Speakers

11:20 AM

Role of neo-adjuvant chemotherapy and surgery for locally advanced cervical cancer

Lisa Bazzett

11:40 AM

Management of locally advanced cervical cancer

Michelle Vaughan

11:55 AM

Nodal management of vulva cancer

Ruth Angell

12:10 PM

Losing fertility (patient’s perspective)

Amanda Kisbee [video]

12:15 PM

Panel Discussion

All

Abstract 1: BEACON: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer. Abstract 2: Evaluating patterns of care in Mucinous Ovarian Cancer in Australia using the National Gynae Oncology Registry

12:30 PM

Sathya Manoharan

12:40 PM

Niveditha Rajadevan

LUNCH – The Atrium and Canberra Room

12:50 PM

ANZGOG INFORMATION Session Chairs: Clare Scott AM & Alison Evans

1:40 PM – 2:05 PM

Speakers

Looking Forward to 2028: Realising the Strategic Plan [Gynaceological Cancer Transformation Initiative, State of the Nation in Uterine Cancer, OASIS II, funding research] Panel Discussion

Clare Scott AM & Alison Evans Panel: Anna DeFazio AM, Linda Mileshkin, George Au-Yeung & John Andrews

1:40 PM

TRIAL CONCEPTS Session Chairs: Paul Cohen & Yoland Antill

2:10 PM – 3:35 PM

Speakers

2:10 PM

Engaging Our Community Volunteers

Bree Stevens & community representatives

2:20 PM

Priority Populations and our Research – Equity and Access

Paul Cohen

2:30 PM

The role of the Asia-Pacific Gynaecological Oncology Trials Group [APGOT]

David Tan

Concept 1: OrCaS: MOC – Organoid Cancer Screening for Mucinous Ovarian Carcinoma [incl 5 mins Q&A]

2:35 PM

Kylie Gorringe & Niveditha Rajadevan

2:55 PM

Concept 2: EndCa Project [incl 5 min Q&A]

Rachel Delahunty

3:15 PM

Concept 3: IMPACT [incl 5 min Q&A]

Peey-Sei Kok

AFTERNOON TEA – The Atrium and Canberra Room

3:35 PM

HAPPY 25 th BIRTHDAY ANZGOG Session Chairs: Bryony Simcock & Emma Allanson

4:00 PM – 5:00 PM

4:00 PM

Surprise!

4:30 PM – 5:00 PM

Affirmative Team: Alison Brand AM, Alison Davis, Paul Cohen Negative Team: Michelle Vaughan, George Au-Yeung

Debate: Session Chairs: Bryony Simcock & Emma Allanson

CONFERENCE DINNER & AWARDS National Gallery of Australia

7:00 PM – 11:00 PM

Sponsored by:

6

CONFERENCE DAY 2 – FRIDAY 7 MARCH – Federation Ballroom

Breakfast Symposium: The role of immunotherapy in cervical cancer Moderator: Yoland Antill

7:15 AM – 8:15 AM

Sponsored by:

QUALITY OF LIFE & SURVIVORSHIP 25 years but 25 long years: Quality of life and survival for people with gynae cancer Session Chairs: Haryana Dhillon, Alison Davis, Bronwyn Jennings, Gwyneth Capes & Jane Power

8:30 AM – 10:20 AM

Speakers

8:30 AM

In the beginning there was quality of life assessment

Michael Friedlander AM

8:45 AM

ANZGOG is the MOST

Rachel Campbell

9:00 AM

Lived experience – Answer the question

TBC

9:10 AM

Are we ever too old for quality of life?

Christopher Steer

9:20 AM

What is the question?

Chindhu Shunmuga Sundaram

9:30 AM

Plenary Discussion

All

Abstract 3: Value of routine pelvic examination in the follow-up of patients receiving adjuvant radiation therapy for endometrial cancer: an Australian tertiary-centre experience

10:00 AM

Matthew Knox

10:10 AM

Abstract 4: Homologous recombination deficiency testing of ascites in ovarian cancer patients

Marta Preston

MORNING TEA – The Atrium and Canberra Room

10:20 AM

UTERINE CANCER Session Chairs: David Chang & Michelle Wilson

10:55 AM – 12:30 PM

Speakers

10:55 AM

Help, I’ve been diagnosed with a rare cancer (patient’s perspective)

Ali Crawford (video)

11:00 AM

Projections: The future of the LMS Landscape

Michelle Harrison

11:15 AM

The impact of molecular characteristics on endometrial cancer

Carien Creutzberg

11:35 AM

Should the surgical paradigms that apply in ovarian cancer apply in endometrial cancer?

Cecile Bergzoll

11:50 AM

Panel discussion

All

Abstract 5: Predicting immunotherapy outcomes in endometrial cancer using multiomic cell-free DNA analysis Abstract 6: C entre of R esearch E xcellence to Improve the Qu ALI ty of Sur V ival in Gynaecological Cancer Pati E nts (CRE ALIVE WELL) LUNCH – The Atrium and Canberra Room Research Advisory Committee (RAC) meeting – Assembly Room

12:10 PM

Lesley Arends

12:20 PM

Eva Baxter

12:30 PM

RECRUITING TRIALS UPDATE Session Chairs: Lois Eva and Paul Cohen

1:25 PM – 2:15 PM

Speakers

1:25 PM 1:30 PM 1:35 PM 1:40 PM 1:45 PM 1:50 PM 1:55 PM 2:00 PM 2:05 PM 2:10 PM

Trial 1 – Ignite Trial 2 – EPOCH

George Au-Yeung Clare Scott AM Alison Brand AM

Trial 3 – Taper

Trial 4 – Domenica

Alison Davis Alison Davis Yoland Antill

Trial 5 – PEACE

Trial 6 – EXPORT42

Trial 7 - ADELE

Linda Mileshkin

Trial 8 – Paragon II

Chee Lee

Trial 9 – ENDO 3 & ANVU

QCGC Collaboration Representative

Q&A

AFTERNOON TEA – The Atrium and Canberra Room

2:15 PM

OVARIAN CANCER Session Chairs: Michael Burling & Cristina Mapagu

2:35 PM – 4:10 PM

Speakers

2:35 PM 2:55 PM 3:05 PM 3:20 PM 3:35 PM 3:50 PM

Racial disparities in the management of ovarian cancer

David Tan

ICON-9 Results Presentation

Linda Mileshkin

Current and emerging treatments in the management of Low-grade serous carcinoma

Cristina Mapagu

Combatting ageism in clinical trials: Is 80 the new 40?

Alison Brand AM

Where to in ovarian cancer research: where to from here?

Elizabeth Christie

Panel discussion

All

4:10 PM – 4:20 PM

Abstract Awards & Close of Conference

Clare Scott AM

4:30 PM

Shuttle Bus departs to Airport

Poster Abstracts

Poster Session Wednesday, 5.30pm - 6.30pm, The Gallery, Hyatt Canberra

Sponsored by:

Number Title

Presenting Author

101 Inclusiveness in patient-reported outcome measures (PROMs): a resource about translations and cross-cultural validations from the Cancer Australia Quality of Life Technical Service (CQUEST) 102 Using Patient-Reported Outcome Measures in Cancer Clinical Trials: Perspectives For and Against a ‘Modular Approach’

Carrie-Anne Ng

Carrie-Anne Ng Natalie Williams Natalie Williams Natalie Williams Caoimhe O'Sullivan

104

Educational needs of patients with a pre-disposition to vulval cancer: an audit and cross-sectional survey

105 Centralising care of Gestational Trophoblastic Disease in Western Australia: a consumer satisfaction evaluation

106 107

Expectations for gynaecological cancer nursing guidance development: A qualitative exploration

Cervical cancer awareness amongst Australian women

108 Ovarian cancer clinical trials awareness, information access and participation: an Australian cross-sectional study

Natalie Williams

109 Patterns of care for patients with cervical cancer in Western Australia at a state-wide tertiary referral centre between 2009 and 2018. 110 Differences in the cervical cancer cohort, treatment provision and survival in Western Australia at a state-wide tertiary referral centre between 2009-2013 and 2014-2018.

Kate Mannolini

Kate Mannolini

111

The National Gynae-Oncology Registry (NGOR). Past, present and future.

Robert Rome

112 Lessons from the ovarian cancer research sector: informing a new five-year Research Impact Strategy for the OCRF 113 A mixed methods approach to identify unwarranted variations, causes and improvement priorities in Victorian endometrial cancer care

David Hunt

Yoland Antill

114

Return of research results: Implementation of the INOVATe study Ethically Defensible Plan

Pamela Provan

115 “The telehealth means I get distance from the hospital so I don’t feel so much like a patient”: A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations. 116 What works? A systematic review of mathematical models of ovarian cancer prevention, detection, and treatment Ovarian cancer clinical trial recommendations guided by molecular analysis in the INOVATe study Studying ovarian cancer subclones and their tumour microenvironments using spatial transcriptomics 120 Pre-clinical Evidence for Ivacaftor as a Potential Repurposed Therapy for High-Grade Serous Ovarian Cancer 117 118

Rachel Campbell

Kirstie McLoughlin

Cristina Mapagu

Alistair Forrest Michelle Brown Anastasia Gandini

121 122

Isolating tumour cells from HGSOC patient-derived ascites to improve disease modelling Combination effect of MEK and CDK4/6 inhibition in low-grade serous ovarian cancer cell lines

Sarah Ho

123 Exposure of ovarian clear cell carcinoma, an endometriosis-associated malignancy, to endometrial stromal cells increases inflammatory chemokines and promotes cancer-associated behaviours 124 High-throughput in vitro screening of potential repurposed drugs for treatment of high-grade serous ovarian cancer

Kristie-Ann Dickson

Michelle W Wong Brown Jacinta L Simmons Nikita Rosendahl Bayley Matthews Catherine J Kennedy

125 126 127

A multi-omic approach to study ovarian cancer treatment resistance.

Investigating the role of human dendritic cells in ovarian cancer

Drug repurposing screen targeting cell cycle checkpoint regulators in high-grade serous ovarian cancer

128 GynBiobank at Westmead: Providing essential resources for translational gynaecological cancer research and clinical trials. 129 Development of PARP inhibitor-resistant high-grade serous ovarian cancer cell lines and discovery of a synergistic drug combination that increases sensitivity to PARP inhibition 130 Using molecular signatures to assess chromosomal instability in High Grade Serous Ovarian Cancer from shallow whole genome sequencing 131 Circulating tumour DNA in patients undergoing chemotherapy for ovarian cancer detected using a novel, highly sensitive quantitative PCR technique

Tao Xie

Merridee Wouters

Kristina Warton

132

Using modified glucose to induce ovarian cancer cell death and promote anti-tumor immunity

Brittney S Harrington

133 Validation of ProMisE/TransPORTEC system for molecular classification of endometrial cancer in an Australian Cohort

Molly Muir

134 135 137

The Role of Visceral Adipose in Endometrial Cancer: Uncovering Mechanisms and Insights Reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer

Serena SG Gallozzi

Jian Kang

Targeting the nucleoli as a strategy to treat ovarian cancer

Shalini Sundramurthi Chelliah

138 Mutation profiling and molecular analysis in the INOVATe study: towards a personalised approach to the management of ovarian cancer patients

Natalie Bouantoun

139

Uncovering mechanisms of PARP inhibitor resistance in high-grade serous ovarian cancer

Zoe Phan

8

Floorplan

BANQUET ENTRANCE

ASSEMBLY ROOM

GALLERY

COMMUNITY VOLUNTEERS LOUNGE

Abbvie EISAI

NGOR

OCO

THE ATRIUM

AZ

ANZGOG

AZ

CANBERRA ROOM

SOUTH BALLROOM

FEDERATION BALLROOM

NORTH BALLROOM

Daichi Sankyo

MSD

Catering

Illumina

Registration Desk

Catering

Illumina

GSK

MALE TOILETS

FEMALE TOILETS

LIFT LOBBY

ASSEMBLY ROOM

GALLERY

THE ATRIUM

FEDERATION BALLROOM

CANBERRA ROOM

CENTENARY BALLROOM

LAVENDER COURTYARD

10

The most common TEAEs that occurred in >30% patients treated with JEMPERLI plus CP vs CP at 36.6 months follow-up were nausea (54.4% and 46.3%), alopecia (53.9% and 50.0%), fatigue (52.3% and 54.9%), peripheral neuropathy (44.0% and 41.9%), anaemia (37.8% and 42.7%), arthralgia (37.3% and 35.4%), constipation (34.9% and 36.2%) and diarrhoea (31.5% and 29.3%). 1 The most common treatment-emergent irAEs for JEMPERLI + CP vs CP were hypothyroidism (12.0% vs 2.8%), rash (7.1% vs 2.0%), arthralgia (6.6% vs 6.5%), and increased alanine aminotransferase (6.2% vs 1.2%). 1 The first and only immunotherapy in combination with CP to demonstrate overall survival in dMMR advanced or recurrent endometrial cancer patients vs CP: 1 • JEMPERLI + CP demonstrated a 68% reduction in risk of death vs CP in dMMR patients 1†# † Median OS was not reached with JEMPERLI + CP vs 31.4 months CP in dMMR patients (HR=0.32, 95% CI: 0.17-0.63, nominal P=0.0002; prespecified exploratory endpoint, median 36.6 months follow-up). 1 # Median PFS for JEMPERLI + CP not reached vs 7.7 months for CP in dMMR patients (HR 0.28, 95% CI: 0.16-0.50, P<0.0001; primary endpoint, median 24 months follow-up). 2,3

NOW PBS LISTED 4

Scan the QR code to learn more about JEMPERLI

JEMPERLI (dostarlimab) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer. 2 PBS LISTED: JEMPERLI Authority Required (STREAMLINED). Refer to PBS Schedule for full information. Please review product information before prescribing. Product information is available at www.gsk.com.au/jemperli or by scanning the QR code. ▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems Abbreviations: CI , confidence interval; CP, carboplatin-paclitaxel; dMMR , mismatch repair deficient; HR , hazard ratio; irAE , immune-related adverse event; MSI-H , microsatellite instability-high; OS, overall survival; PBS , Pharmaceutical Benefits Scheme; PD-1 , programmed cell death protein 1; PFS , progression-free survival; TEAE , treatment-emergent adverse event. References: 1. Powell MA, et al. Ann Oncol. 2024;35(8):728-738. 2. JEMPERLI Product Information. 3 . Mirza MR, et al. N Engl J Med. 2023;388(23):2145-2158 4. Pharmaceutical Benefits Scheme. Dostarlimab. www.pbs.gov.au. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trademarks are owned by or licensed to the GSK group of companies © 2025 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd. Melbourne VIC. PM-AU-DST-JRNA-250001. Date of Approval February 2025.

Thank you to our 2025 Program Committee

Dr Michelle Harrison (Chair) Assoc Prof Emma Allanson (Deputy Chair) Prof Clare Scott AM (ANZGOG Chair)

Assoc Prof Alison Davis Ms Bronwyn Jennings Dr Bryony Simcock Dr Cheslie O’Connor Dr David Chang Ms Gwyneth Capes Assoc Prof Kylie Gorringe Ms Jane Power Dr Lois Eva Dr Maria-Cristina Mapagu Dr Michael Burling Dr Michelle Wilson Dr Nicola Meagher Assoc Prof Pamela Pollock Ms Sue Brew Assoc Prof Yoland Antill

anzgogasm.org.au

#ANZGOG2025ASM